Massachusetts Financial Services Co. MA Reduces Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• Massachusetts Financial Services reduced its Merck stake by 5.6% in the second quarter, selling 15,161 shares and retaining 256,668 shares valued at $36.4 million. Institutional investors collectively own 76.07% of Merck.
• Merck reported quarterly revenue of $16.61 billion, above analyst expectations, while posting an adjusted loss of $0.13 per share and 5.1% year-over-year revenue growth. The company declared a quarterly dividend of $0.85 per share, representing a 2.2% yield.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $135.50, while shares recently traded near $152.21. Investors are also focused on positive Phase 3 results for Merck’s Keytruda-plus-personalized mRNA vaccine combination, though regulatory approval and Keytruda’s eventual patent expiry remain important uncertainties.

Massachusetts Financial Services Co. MA lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 256,668 shares of the company's stock after selling 15,161 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Merck & Co., Inc. were worth $36,394,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Somerset Trust Co increased its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company's stock valued at $1,118,000 after acquiring an additional 81 shares in the last quarter. Stonebridge Financial Group LLC lifted its holdings in shares of Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company's stock valued at $1,124,000 after purchasing an additional 81 shares in the last quarter. Stronghold Wealth Management L.L.C. lifted its holdings in shares of Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company's stock valued at $416,000 after purchasing an additional 82 shares in the last quarter. Lederer & Associates Investment Counsel CA grew its position in shares of Merck & Co., Inc. by 0.9% in the second quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company's stock valued at $1,234,000 after purchasing an additional 84 shares during the last quarter. Finally, Pine Haven Investment Counsel Inc grew its position in shares of Merck & Co., Inc. by 0.6% in the second quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company's stock valued at $1,834,000 after purchasing an additional 86 shares during the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Trading Up 12.6%

Shares of MRK stock opened at $152.21 on Thursday. The firm has a market cap of $375.53 billion, a P/E ratio of 121.77, a PEG ratio of 5.83 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $153.50. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm's 50-day simple moving average is $126.86 and its 200-day simple moving average is $120.74.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.'s revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 11,699 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the business's stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company's stock, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MRK shares. Citigroup began coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective for the company. Guggenheim increased their target price on Merck & Co., Inc. from $145.00 to $146.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Royal Bank Of Canada reissued an "outperform" rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Scotiabank upped their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a "sector outperform" rating in a research report on Tuesday, June 30th. Finally, BMO Capital Markets increased their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and an average price target of $135.50.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Phase 3 melanoma success: Moderna and Merck said their individualized mRNA vaccine, intismeran, combined with Merck’s Keytruda, met the primary endpoint in a large Phase 3 trial. The combination significantly extended recurrence-free survival and reduced the risk of melanoma spreading compared with Keytruda alone. This represents the first positive late-stage result for a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: New growth opportunity for Keytruda: The results could expand Merck’s oncology franchise by pairing Keytruda with a mutation-targeted vaccine. The companies believe thousands of high-risk melanoma patients could eventually benefit, pending regulatory approval targeted for 2027. Similar trials are underway in lung, pancreatic, breast and other cancers. Why this mRNA cancer vaccine is raising new treatment hope
• Positive Sentiment: Strategic importance before patent expiry: A successful vaccine-Keytruda combination could help support Merck’s oncology pipeline as Keytruda’s patent protection is expected to expire later this decade. Unusually heavy call-option activity also indicated heightened bullish trading interest.
• Neutral Sentiment: Broader market support: Relief in bond markets helped lift rate-sensitive healthcare stocks generally, providing an additional supportive backdrop for Merck’s move. However, the company’s advance was primarily tied to the vaccine announcement.
• Negative Sentiment: Important uncertainties remain: The companies released topline results, while investors and analysts await complete trial data. The vaccine still requires regulatory approval, and the commercial opportunity, pricing and longer-term benefits are not yet established. Merck also faces substantial future pressure from Keytruda’s eventual loss of exclusivity.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source